Tags

Type your tag names separated by a space and hit enter

When stem cells meet immunoregulation.
Int Immunopharmacol. 2009 May; 9(5):596-8.II

Abstract

The clinical use of stem cells to prevent tissue injury or reconstruct damaged organs is constrained by different ethical and biological issues. Whereas the use of adult stem cells isolated from differentiated tissues is advantageous from the ethical point of view, the immune response of a host to implants of either embryonic or adult stem cells remains a critical problem. Embryonic stem cells can be rejected by an immunocompetent recipient as well as some types of adult stem cells. There is, however, a population of adult stem cells able to differentiate into the three mesenchymal lineages, osteocytes, chondrocytes, adipocytes that have the additional capacity of modulating the immune response by the activation of disparate mechanisms, among which the generation of antigen-specific CD4(+)CD25(+)FoxP3(+) regulatory T lymphocytes. This short review will focus on the immunological properties of embryonic and adult stem cells are, with particular emphasis on the immunomodulatory function of mesenchymal stem cells and their interactions with regulatory T lymphocytes.

Authors+Show Affiliations

Department of Oncology, Biology, and Genetics, University of Genova, Genova, Italy.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19539568

Citation

Tasso, Roberta, and Giuseppina Pennesi. "When Stem Cells Meet Immunoregulation." International Immunopharmacology, vol. 9, no. 5, 2009, pp. 596-8.
Tasso R, Pennesi G. When stem cells meet immunoregulation. Int Immunopharmacol. 2009;9(5):596-8.
Tasso, R., & Pennesi, G. (2009). When stem cells meet immunoregulation. International Immunopharmacology, 9(5), 596-8. https://doi.org/10.1016/j.intimp.2009.01.014
Tasso R, Pennesi G. When Stem Cells Meet Immunoregulation. Int Immunopharmacol. 2009;9(5):596-8. PubMed PMID: 19539568.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - When stem cells meet immunoregulation. AU - Tasso,Roberta, AU - Pennesi,Giuseppina, Y1 - 2009/01/29/ PY - 2009/01/21/received PY - 2009/01/22/accepted PY - 2009/6/23/entrez PY - 2009/6/23/pubmed PY - 2010/1/6/medline SP - 596 EP - 8 JF - International immunopharmacology JO - Int. Immunopharmacol. VL - 9 IS - 5 N2 - The clinical use of stem cells to prevent tissue injury or reconstruct damaged organs is constrained by different ethical and biological issues. Whereas the use of adult stem cells isolated from differentiated tissues is advantageous from the ethical point of view, the immune response of a host to implants of either embryonic or adult stem cells remains a critical problem. Embryonic stem cells can be rejected by an immunocompetent recipient as well as some types of adult stem cells. There is, however, a population of adult stem cells able to differentiate into the three mesenchymal lineages, osteocytes, chondrocytes, adipocytes that have the additional capacity of modulating the immune response by the activation of disparate mechanisms, among which the generation of antigen-specific CD4(+)CD25(+)FoxP3(+) regulatory T lymphocytes. This short review will focus on the immunological properties of embryonic and adult stem cells are, with particular emphasis on the immunomodulatory function of mesenchymal stem cells and their interactions with regulatory T lymphocytes. SN - 1878-1705 UR - https://www.unboundmedicine.com/medline/citation/19539568/When_stem_cells_meet_immunoregulation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1567-5769(09)00029-0 DB - PRIME DP - Unbound Medicine ER -